1
|
Chai Y, Xu Y, Xia Z, Huang X, Zhang L, Jiang Z. Study on the effects of Zhuanggu Guanjie Pill, a modern Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. J Ethnopharmacol 2021; 281:114521. [PMID: 34390794 DOI: 10.1016/j.jep.2021.114521] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 07/31/2021] [Accepted: 08/11/2021] [Indexed: 06/13/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Zhuanggu Guanjie Pill (ZGGJP), a modern Chinese medicine formula, is composed of 12 herbs and has been used to treat osteoporosis in China for almost 30 years. However, no in vivo study of the influences of ZGGJP on the cytochrome P450 (CYP) activities have been reported. AIM OF THE STUDY The aim of this study was to evaluate the effects of ZGGJP on the activities and the mRNA expression of CYP enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A) and their corresponding nuclear receptor levels in rats. MATERIALS AND METHODS After 7 days oral treatment of ZGGJP at low- and high-dose, cocktail solution was given to rats. Blood samples were collected at series of time points. The plasma concentrations of probe drugs and their corresponding metabolites were determined by UPLC-MS/MS. The influence of ZGGJP on the activities of seven CYPs were evaluated the metabolic ratios (Cmax and AUC0-t) for metabolites/probe drugs. In addition, the effects of ZGGJP on the mRNA expression of CYPs and their corresponding nuclear receptors in rat liver were evaluated by real-time PCR. RESULTS ZGGJP showed significant inductive effects on CYP1A2 and CYP2B6 of both male and female rats. The influence of ZGGJP on CYP2C9 and CYP3A showed gender difference. ZGGJP could induce the activities of CYP2C9 and CYP3A in female rats, but have no influence on the activities in male rats. ZGGJP had no effects on CYP2D6, CYP2C19 and CYP2E1. The mRNA expression results of CYPs were in accordance with the pharmacokinetic results. The mRNA expression levels of constitutive androstane receptor (CAR) and vitamin D receptor (VDR) were increased significantly in female rats at high dosage, but no significant changes were observed in male rats. CONCLUSION ZGGJP had inductive effects on CYP1A2 and CYP2B6 in both male and female rats. The results showed that ZGGJP could induce the activities of CYP2C9 and CYP3A in female rats, but had no effect in male rats. This may suggest that the influence of ZGGJP on CYP2C9 and CYP3A exhibit gender difference. The inductive effects of ZGGJP on the activities of CYPs, exhibiting gender difference, may be regulated by CAR and VDR. Therefore, co-administration of ZGGJP with other drugs, especially using CYP2C9 and CYP3A substrates in females, may need dose adjustment to avoid herb-drug interaction.
Collapse
Affiliation(s)
- Yuanyuan Chai
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 210009, China
| | - Yunxia Xu
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 210009, China
| | - Ziyin Xia
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 210009, China
| | - Xin Huang
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 210009, China; Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing, 210009, China
| | - Luyong Zhang
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 210009, China; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
| | - Zhenzhou Jiang
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, 210009, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
| |
Collapse
|
2
|
Stiripentol (Diacomit) for Dravet syndrome. Med Lett Drugs Ther 2021; 63:e48-50. [PMID: 33976090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
|
3
|
Custodio JM, Donaldson KM, Hunt HJ. An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes. J Clin Pharmacol 2021; 61:244-253. [PMID: 32869328 PMCID: PMC7818505 DOI: 10.1002/jcph.1731] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 08/10/2020] [Indexed: 11/06/2022]
Abstract
Relacorilant is a selective modulator of the glucocorticoid receptor in development for the treatment of several serious diseases. The widely used cocktail method was employed to assess relacorilant's effect on various cytochrome P450 (CYP) drug metabolizing enzymes in vitro and in vivo. Inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2B6, CYP2C8, CYP3A4, and CYP3A5 as well as induction of CYP1A2, CYP2B6, and CYP3A4 were assessed in vitro (relacorilant concentrations up to 10 µM). A clinical study in healthy subjects (n = 27) evaluated the inhibition of CYP3A4, CYP2C8, and CYP2C9 in vivo by administering single doses of probe CYP substrates (midazolam, pioglitazone, and tolbutamide) alone and in combination with relacorilant (350 mg). Pharmacokinetic sampling was conducted, and safety was assessed throughout the study. Pharmacokinetic parameters were evaluated using 90% confidence intervals of the geometric least squares mean ratios of test (probe substrate with relacorilant) vs reference (probe substrate alone) using boundaries of 80% to 125%. In vitro, relacorilant inhibited CYP3A4, CYP2C8, and CYP2C9 but did not meaningfully affect the activity of the other CYP enzymes evaluated. Consistent with the in vitro data, relacorilant was shown to be a strong CYP3A inhibitor in vivo (>8-fold increase in midazolam area under the concentration versus time curve from time zero to the last quantifiable concentration and area under the concentration versus time curve from time zero extrapolated to infinity). Coadministration of relacorilant with drugs highly dependent on CYP3A for clearance is expected to increase the concentrations of these drugs. Importantly, clinical evaluation of relacorilant showed no inhibition of CYP2C8 or CYP2C9 in vivo. Accordingly, drugs that are substrates of only CYP2C8 and/or CYP2C9 can be coadministered with relacorilant without dose adjustment.
Collapse
|
4
|
Table: Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2020; 62:e152-3. [PMID: 32960871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
|
5
|
Treiber A, Delahaye S, Seeland S, Gnerre C. The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern. Pharmacol Res Perspect 2020; 8:e00619. [PMID: 32613761 PMCID: PMC7330163 DOI: 10.1002/prp2.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 05/13/2020] [Accepted: 05/14/2020] [Indexed: 11/18/2022] Open
Abstract
The dual endothelin receptor antagonist macitentan was approved in 2013 for the treatment of pulmonary arterial hypertension. Macitentan is an inducer of cytochrome P450 expression in vivo in animal species but not in man. In rat and dog, changes in P450 expression manifest as autoinduction upon repeat dosing. The induction pattern, however, significantly differed between both species, and between male and female rats. While macitentan exposure steadily declined with dose in the dog, P450 induction was saturable in the rat reaching levels of 40%-60% and 60%-80% at steady-state in male and female animals, respectively. The nature and number of P450 enzymes involved in macitentan clearance were identified as a major reason for the observed species differences. In the dog, macitentan was metabolized by a single P450 enzyme, that is, Cyp3a12, whereas several members of the Cyp2c and Cyp3a families were involved in the rat. Macitentan selectively upregulated Cyp3a expression in rat, whereas the expression of the Cyp2c enzymes involved in macitentan metabolism remained mostly unchanged, eventually leading to a higher contribution of Cyp3a upon induction. Macitentan also induced CYP3A4 expression in human hepatocytes via initial activation of the human pregnane X receptor. No such induction was evident in humans at the therapeutic macitentan dose of 10 mg as shown in a clinical drug-drug interaction study with the CYP3A4 substrate sildenafil.
Collapse
Affiliation(s)
- Alexander Treiber
- Department of Non‐Clinical Drug Metabolism and PharmacokineticsIdorsia Pharmaceuticals LtdAllschwilSwitzerland
| | - Stephane Delahaye
- Department of Non‐Clinical Drug Metabolism and PharmacokineticsIdorsia Pharmaceuticals LtdAllschwilSwitzerland
| | - Swen Seeland
- Department of Non‐Clinical Drug Metabolism and PharmacokineticsIdorsia Pharmaceuticals LtdAllschwilSwitzerland
| | - Carmela Gnerre
- Department of Non‐Clinical Drug Metabolism and PharmacokineticsIdorsia Pharmaceuticals LtdAllschwilSwitzerland
| |
Collapse
|
6
|
Heinig R, Gerisch M, Bairlein M, Nagelschmitz J, Loewen S. Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications. Eur J Drug Metab Pharmacokinet 2020; 45:433-444. [PMID: 32125665 DOI: 10.1007/s13318-020-00610-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND AND OBJECTIVES In vivo studies were performed with the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone to assess the relevance of inductive and/or inhibitory effects on cytochrome P450 (CYP) enzymes observed in vitro. METHODS CYP isoenzyme-specific substrates were incubated in vitro with finerenone or its metabolites to investigate reversible and irreversible inhibitory as well as inductive potential. Three crossover studies in healthy male volunteers investigated the effects of finerenone (20 mg orally) on the pharmacokinetics of the index substrates midazolam (CYP3A4, n = 30), repaglinide (CYP2C8, n = 28) and warfarin (CYP2C9, n = 24). RESULTS Finerenone caused direct inhibitory effects on CYP activities in vitro in the rank order CYP2C8, CYP1A1 > CYP3A4 > CYP2C9 and CYP2C19, but not on other major CYP isoforms. Moreover, irreversible inhibition of CYP3A4 was observed. The major metabolites of finerenone demonstrated minor reversible inhibition of CYP1A1, CYP2C9 and CYP3A4 with no hint of time-dependent inhibition of any CYP isoform. Calculations from in vitro data according to regulatory guidelines suggested likely inhibition of CYP2C8 and CYP3A4 in vivo, whereas this was not the case for CYP1A1, CYP2C9 and CYP2C19. Furthermore, finerenone and three of its metabolites were inducers of CYP3A4 in vitro with predicted weak-to-moderate in vivo relevance. Studies in healthy volunteers, prompted by these results, demonstrated no effect of finerenone on CYP isoenzymes for which in vitro data had indicated potential inhibition or induction. CONCLUSION Administration of finerenone 20 mg once daily confers no risk of clinically relevant drug-drug interactions with substrates of cytochrome P450 enzymes.
Collapse
Affiliation(s)
- Roland Heinig
- Bayer AG, Research and Development, Pharmaceuticals, Clinical Sciences, Wuppertal, Germany.
| | - Michael Gerisch
- Bayer AG, Research and Development, Pharmaceuticals, DMPK, Wuppertal, Germany
| | - Michaela Bairlein
- Bayer AG, Research and Development, Pharmaceuticals, DMPK, Wuppertal, Germany
| | - Johannes Nagelschmitz
- Bayer AG, Research and Development, Pharmaceuticals, Clinical Sciences, Wuppertal, Germany
| | | |
Collapse
|
7
|
Chayawan C, Toma C, Benfenati E, Caballero Alfonso AY. Towards an Understanding of the Mode of Action of Human Aromatase Activity for Azoles through Quantum Chemical Descriptors-Based Regression and Structure Activity Relationship Modeling Analysis. Molecules 2020; 25:molecules25030739. [PMID: 32046297 PMCID: PMC7037385 DOI: 10.3390/molecules25030739] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 02/06/2020] [Accepted: 02/06/2020] [Indexed: 11/16/2022] Open
Abstract
Aromatase is an enzyme member of the cytochrome P450 superfamily coded by the CYP19A1 gene. Its main action is the conversion of androgens into estrogens, transforming androstenedione into estrone and testosterone into estradiol. This enzyme is present in several tissues and it has a key role in the maintenance of the balance of androgens and estrogens, and therefore in the regulation of the endocrine system. With regard to chemical safety and human health, azoles, which are used as agrochemicals and pharmaceuticals, are potential endocrine disruptors due to their agonist or antagonist interactions with the human aromatase enzyme. This theoretical study investigated the active agonist and antagonist properties of “chemical classes of azoles” to determine the relationships of azole interaction with CYP19A1, using stereochemical and electronic properties of the molecules through classification and multilinear regression (MLR) modeling. The antagonist activities for the same substituent on diazoles and triazoles vary with its chemical composition and its position and both heterocyclic systems require aromatic substituents. The triazoles require the spherical shape and diazoles have to be in proper proportion of the branching index and the number of ring systems for the inhibition. Considering the electronic aspects, triazole antagonist activity depends on the electrophilicity index that originates from interelectronic exchange interaction (ωHF) and the LUMO energy (ELUMOPM7), and the diazole antagonist activity originates from the penultimate orbital (EHOMONLPM7) of diazoles. The regression models for agonist activity show that it is opposed by the static charges but favored by the delocalized charges on the diazoles and thiazoles. This study proposes that the electron penetration of azoles toward heme group decides the binding behavior and stereochemistry requirement for antagonist activity against CYP19A1 enzyme.
Collapse
Affiliation(s)
- Chayawan Chayawan
- Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, Istituto di RicercheFarmacologiche “Mario Negri”—IRCCS, Via Mario Negri, 2, 20156 Milano, Italy; (C.C.); (C.T.)
| | - Cosimo Toma
- Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, Istituto di RicercheFarmacologiche “Mario Negri”—IRCCS, Via Mario Negri, 2, 20156 Milano, Italy; (C.C.); (C.T.)
| | - Emilio Benfenati
- Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, Istituto di RicercheFarmacologiche “Mario Negri”—IRCCS, Via Mario Negri, 2, 20156 Milano, Italy; (C.C.); (C.T.)
- Correspondence: (E.B.); (A.Y.C.A.); Tel.: +39-023-901-4420 (E.B.); +39-388-794-3483 (A.Y.C.A.)
| | - Ana Y. Caballero Alfonso
- Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, Istituto di RicercheFarmacologiche “Mario Negri”—IRCCS, Via Mario Negri, 2, 20156 Milano, Italy; (C.C.); (C.T.)
- Jozef Stefan International Postgraduate School, Jamovacesta 39, 1000 Ljubljana, Slovenia
- Correspondence: (E.B.); (A.Y.C.A.); Tel.: +39-023-901-4420 (E.B.); +39-388-794-3483 (A.Y.C.A.)
| |
Collapse
|
8
|
Heinrich P, Braunbeck T. Microplastic particles reduce EROD-induction specifically by highly lipophilic compounds in RTL-W1 cells. Ecotoxicol Environ Saf 2020; 189:110041. [PMID: 31816496 DOI: 10.1016/j.ecoenv.2019.110041] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 11/29/2019] [Accepted: 11/30/2019] [Indexed: 06/10/2023]
Abstract
Microplastic particles (MPs) from lipophilic polymers have been shown to efficiently accumulate hydrophobic organic contaminants (HOCs) in aquatic environments. MPs have, therefore, frequently been discussed as vectors for contaminants, enhancing HOC uptake by various organisms after ingestion followed by pollutant release; however, integrative models of sorption argue against this mechanism and even predict cleansing of pollutants from biological systems under particular circumstances. In order to experimentally investigate such a depuration mechanism, RTL-W1 cells were dosed with three 7-ethoxyresorufin-O-deethylase (EROD) inducers of distinct lipophilicity via the medium before adding both native and hexane-purified polyethylene MPs (20-25 μm) to the medium surface. EROD activity was significantly reduced in the presence of MP, the extent of which correlated with the inducers' lipophilicity (KOW) and thus affinity to MP. For hexane-purged MPs and TCDD (KOW = 6.8), MPs reduce the bioavailability by up to 79%; the effect was marginally weaker with benzo[k]fluoranthene (KOW = 6.11) and almost absent with β-Naphthoflavone (KOW = 4.68). Compared to hexane-purged MPs, native particles possessed slightly less detoxification potential. These experimental results corroborate theoretically predicted mechanisms of detoxification via MPs. Yet, it is unclear if, under corresponding conditions in the environment, MPs can compete with organismal tissues for highly lipophilic compounds and, if so, to which degree they may act as a sink reducing the amount of bioavailable pollutants in situ. However, the present results suggest that in scenarios where pollutant-free MPs interact with organisms that accumulated HOCs via other routes of uptake, qualitatively the presence of such a mechanism is likely.
Collapse
Affiliation(s)
- Patrick Heinrich
- Aquatic Ecology and Toxicology Section, Centre for Organismal Studies, University of Heidelberg, Im Neuenheimer Feld 504, D-69120, Heidelberg, Germany.
| | - Thomas Braunbeck
- Aquatic Ecology and Toxicology Section, Centre for Organismal Studies, University of Heidelberg, Im Neuenheimer Feld 504, D-69120, Heidelberg, Germany
| |
Collapse
|
9
|
Abstract
Traditional animal models mimic only the earliest stages of human diabetic nephropathy (DN), which limits their utility to dissect the pathogenesis of progressive disease or test novel therapeutics. In this chapter we describe in detail the experimental procedures required to conduct the Cyp1a1mRen2 rodent model, in which hyperglycemia and renin-dependent hypertension synergize to promote moderate proteinuria, renal fibrosis, and induction of many of the transcriptomic changes observed in the kidney of patients with progressive DN.
Collapse
Affiliation(s)
- Carolynn Cairns
- Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
| | - Bryan Conway
- Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
| |
Collapse
|
10
|
Bernasconi C, Pelkonen O, Andersson TB, Strickland J, Wilk-Zasadna I, Asturiol D, Cole T, Liska R, Worth A, Müller-Vieira U, Richert L, Chesne C, Coecke S. Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study. Toxicol In Vitro 2019; 60:212-228. [PMID: 31158489 PMCID: PMC6718736 DOI: 10.1016/j.tiv.2019.05.019] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Accepted: 05/29/2019] [Indexed: 12/12/2022]
Abstract
CYP enzyme induction is a sensitive biomarker for phenotypic metabolic competence of in vitro test systems; it is a key event associated with thyroid disruption, and a biomarker for toxicologically relevant nuclear receptor-mediated pathways. This paper summarises the results of a multi-laboratory validation study of two in vitro methods that assess the potential of chemicals to induce cytochrome P450 (CYP) enzyme activity, in particular CYP1A2, CYP2B6, and CYP3A4. The methods are based on the use of cryopreserved primary human hepatocytes (PHH) and human HepaRG cells. The validation study was coordinated by the European Union Reference Laboratory for Alternatives to Animal Testing of the European Commission's Joint Research Centre and involved a ring trial among six laboratories. The reproducibility was assessed within and between laboratories using a validation set of 13 selected chemicals (known human inducers and non-inducers) tested under blind conditions. The ability of the two methods to predict human CYP induction potential was assessed. Chemical space analysis confirmed that the selected chemicals are broadly representative of a diverse range of chemicals. The two methods were found to be reliable and relevant in vitro tools for the assessment of human CYP induction, with the HepaRG method being better suited for routine testing. Recommendations for the practical application of the two methods are proposed.
Collapse
Affiliation(s)
| | - Olavi Pelkonen
- Research Unit of Biomedicine/Pharmacology and Toxicology, Faculty of Medicine, Aapistie 5B, University of Oulu, FIN-90014, Finland; Clinical Research Center, Oulu University Hospital, Finland
| | - Tommy B Andersson
- Drug Metabolism and Pharmacokinetics, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | - Judy Strickland
- Integrated Laboratory Systems (contractor supporting NICEATM), Research Triangle Park, North, Carolina, 27709, USA
| | | | - David Asturiol
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Thomas Cole
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Roman Liska
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Andrew Worth
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Ursula Müller-Vieira
- Boehringer Ingelheim, Germany. Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, an der Riss, Germany
| | - Lysiane Richert
- KaLy-Cell, 20A, rue du Général Leclerc, 67115 Plobsheim, France(g) Biopredic International, Parc d'activité de la Bretèche Bâtiment A4, 35760 Saint Grégoire, France
| | - Christophe Chesne
- Biopredic International, Parc d'activité de la Bretèche Bâtiment A4, 35760 Saint Grégoire, France
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy.
| |
Collapse
|
11
|
Vyhlídalová B, Poulíková K, Bartoňková I, Krasulová K, Vančo J, Trávníček Z, Mani S, Dvořák Z. Mono-methylindoles induce CYP1A genes and inhibit CYP1A1 enzyme activity in human hepatocytes and HepaRG cells. Toxicol Lett 2019; 313:66-76. [PMID: 31201936 DOI: 10.1016/j.toxlet.2019.06.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 06/03/2019] [Accepted: 06/11/2019] [Indexed: 01/01/2023]
Abstract
Mono-methylindoles (MMI) were described as agonists and/or antagonists of the human aryl hydrocarbon receptor (AhR). Here, we investigated the effects of MMI on AhR-CYP1A pathway in human hepatocytes and HepaRG cells derived from human progenitor hepatic cells. All MMI, except of 2-methylindole, strongly induced CYP1A1 and CYP1A2 mRNAs in HepaRG cells. Induction of CYP1A genes was absent in AhR-knock-out HepaRG cells. Consistently, CYP1A1 and CYP1A2 mRNAs and proteins were induced by all MMIs (except 2-methylindole), in human hepatocytes. The enzyme activity of CYP1A1 was inhibited by MMIs in human hepatocytes and LS180 colon cancer cells in a concentration-dependent manner (IC50 values from 1.2 μM to 23.8 μM and from 3.4 μM to 11.4 μM, respectively). Inhibition of CYP1A1 activity by MMI in human liver microsomes was much weaker as compared to that in intact cells. Incubation of parental MMI with human hepatocytes either diminished (4-methylindole, 6-methylindole) or enhanced (7-methylindole) their agonist effects on AhR in AZ-AHR reporter cells. In conclusion, overall effects of MMI on AhR-CYP1A pathway in human cells comprise the induction of CYP1A genes through AhR, the inhibition of CYP1A catalytic activity and possibly the metabolic transformation causing loss or gain of AhR agonist activity of parental compounds.
Collapse
Affiliation(s)
- Barbora Vyhlídalová
- Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic
| | - Karolína Poulíková
- Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic
| | - Iveta Bartoňková
- Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic
| | - Kristýna Krasulová
- Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic; Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic
| | - Jan Vančo
- Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic
| | - Zdeněk Trávníček
- Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic
| | - Sridhar Mani
- Department of Genetics and Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
| | - Zdeněk Dvořák
- Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic; Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
| |
Collapse
|
12
|
Lu YY, Du ZY, Li Y, Wang JL, Zhao MB, Jiang Y, Guo XY, Tu PF. Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. J Ethnopharmacol 2018; 225:327-335. [PMID: 30048731 DOI: 10.1016/j.jep.2018.07.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 06/25/2018] [Accepted: 07/21/2018] [Indexed: 06/08/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Baoyuan decoction (BYD), a traditional Chinese medicine (TCM) formula, is composed of four herbs and widely used with western drugs to treat coronary heart disease, aplastic anemia and chronic renal failure in clinic. However, no study of the effect of BYD on the cytochrome P450 (CYP) activities has been reported. AIM OF THE STUDY The purpose of the present study was to evaluate the potential influences of BYD on the activities of seven CYP isozymes (CYP1A2, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4) in rats. MATERIALS AND METHODS A sensitive and selective UPLC-MS/MS method for simultaneous determination of seven probe drugs and internal standard (IS) in rat plasma was developed and validated. The influence of BYD on the activities of CYP isozymes and mRNA expression levels were carried out by comparing plasma pharmacokinetics and real-time reverse transcription-polymerase chain reaction (RT-PCR) of probe drugs between control and BYD treatment groups respectively. RESULTS The calibration curve were linear, with correlation coefficient (r) > 0.99 for seven probe drugs. The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%. Compared with control group, BYD at low (1.46 g/kg) and high (7.30 g/kg) dosages could significantly increase Cmax and AUC0-t of chlorzoxazone and testosterone, while decrease AUC0-t of phenacetin at high dosage and increase AUC0-t of tolbutamide and metoprolol. Additionally, BYD had increased AUC0-t of bupropion at low dosage and decreased it at high dosage. The mRNA expression results were in accordance with those of pharmacokinetic. CONCLUSION BYD exhibited inhibitory effects on CYP2C9, CYP2E1, and CYP3A4. Moreover, BYD had induction effects on CYP1A2, and CYP2D6 activities. However, no significant change in CYP2C19 activity was observed. It would be useful for the safe and effective usage of BYD in clinic.
Collapse
Affiliation(s)
- Ying-Yuan Lu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
| | - Zhi-Yong Du
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
| | - Yan Li
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
| | - Jin-Long Wang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
| | - Ming-Bo Zhao
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
| | - Yong Jiang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
| | - Xiao-Yu Guo
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China
| | - Peng-Fei Tu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China.
| |
Collapse
|
13
|
Volpe DA, Xu Y, Sahajwalla CG, Younis IR, Patel V. Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review. J Pharm Sci 2018; 107:2983-2991. [PMID: 30205091 DOI: 10.1016/j.xphs.2018.08.025] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Revised: 08/20/2018] [Accepted: 08/24/2018] [Indexed: 11/19/2022]
Abstract
Methadone is utilized for the treatment of individuals with opiate dependence. Methadone undergoes N-demethylation by multiple cytochrome P450 (CYP) enzymes including CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2C9, and CYP2C8. In vivo, polymorphism effects on methadone systemic exposure have been noted for CYP2B6, CYP3A4, and CYP2D6. Clinical drug interaction studies with antiviral drugs in methadone maintenance treatment patients yield varying results on methadone pharmacokinetics and pharmacodynamics. In general, CYP inhibitors altered methadone exposure with no adverse effects. CYP inducers generally decreased methadone exposure with some reports of withdrawal symptoms in the subjects. Interaction studies with antiviral drug combinations yielding differing results depend on the enzyme(s) affected. For certain antiviral medicines which are dual inhibitor(s) and inducer(s) for CYP enzymes, their effect on methadone pharmacokinetics can change with time since the effect of induction is usually delayed compared to the effect of inhibition.
Collapse
Affiliation(s)
- Donna A Volpe
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993.
| | - Yun Xu
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993
| | - Chandrahas G Sahajwalla
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993
| | - Islam R Younis
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993
| | - Vikram Patel
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993
| |
Collapse
|
14
|
Liu D, Qin S, Ray B, Kalari KR, Wang L, Weinshilboum RM. Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction. Drug Metab Dispos 2018; 46:1372-1381. [PMID: 29980579 PMCID: PMC6090174 DOI: 10.1124/dmd.118.082164] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2018] [Accepted: 06/28/2018] [Indexed: 12/20/2022] Open
Abstract
CYP1A1 expression can be upregulated by the ligand-activated aryl hydrocarbon receptor (AHR). Based on prior observations with estrogen receptors and estrogen response elements, we tested the hypothesis that single-nucleotide polymorphisms (SNPs) mapping hundreds of base pairs (bp) from xenobiotic response elements (XREs) might influence AHR binding and subsequent gene expression. Specifically, we analyzed DNA sequences 5 kb upstream and downstream of the CYP1A1 gene for putative XREs. SNPs located ±500 bp of these putative XREs were studied using a genomic data-rich human lymphoblastoid cell line (LCL) model system. CYP1A1 mRNA levels were determined after treatment with varying concentrations of 3-methylcholanthrene (3MC). The rs2470893 (-1694G>A) SNP, located 196 bp from an XRE in the CYP1A1 promoter, was associated with 2-fold variation in AHR-XRE binding in a SNP-dependent fashion. LCLs with the AA genotype displayed significantly higher AHR-XRE binding and CYP1A1 mRNA expression after 3MC treatment than did those with the GG genotype. Electrophoretic mobility shift assay (EMSA) showed that oligonucleotides with the AA genotype displayed higher LCL nuclear extract binding after 3MC treatment than did those with the GG genotype, and mass spectrometric analysis of EMSA protein-DNA complex bands identified three candidate proteins, two of which were co-immunoprecipitated with AHR. In conclusion, we have demonstrated that the rs2470893 SNP, which maps 196 bp from a CYP1A1 promoter XRE, is associated with variations in 3MC-dependent AHR binding and CYP1A1 expression. Similar "distant SNP effects" on AHR binding to an XRE motif and subsequent gene expression might occur for additional AHR-regulated genes.
Collapse
Affiliation(s)
- Duan Liu
- Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota
| | - Sisi Qin
- Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota
| | - Balmiki Ray
- Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota
| | - Krishna R Kalari
- Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota
| | - Liewei Wang
- Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota
| | - Richard M Weinshilboum
- Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
15
|
Forsch K, Schöning V, Disch L, Siewert B, Unger M, Drewe J. Development of an in vitro screening method of acute cytotoxicity of the pyrrolizidine alkaloid lasiocarpine in human and rodent hepatic cell lines by increasing susceptibility. J Ethnopharmacol 2018; 217:134-139. [PMID: 29454024 DOI: 10.1016/j.jep.2018.02.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 02/08/2018] [Accepted: 02/12/2018] [Indexed: 06/08/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Pyrrolizidine alkaloids (PAs) are secondary plant ingredients formed in many plant species to protect against predators. PAs are generally considered acutely hepatotoxic, genotoxic and carcinogenic. Up to now, only few in vitro and in vivo investigations were performed to evaluate their relative toxic potential. AIM OF THE STUDY The aim was to develop an in vitro screening method of their cytotoxicity. MATERIALS AND METHODS Human and rodent hepatocyte cell lines (HepG2 and H-4-II-E) were used to assess cytotoxicity of the PA lasiocarpine. At concentrations of 25 µM up to even 2400 µM, no toxic effects in neither cell line was observed with standard cell culture media. Therefore, different approaches were investigated to enhance the susceptibility of cells to PA toxicity (using high-glucose or galactose-based media, induction of toxifying cytochromes, inhibition of metabolic carboxylesterases, and inhibition of glutathione-mediated detoxification). RESULTS Galactose-based culture medium (11.1 mM) increased cell susceptibility in both cell-lines. Cytochrome P450-induction by rifampicin showed no effect. Inhibition of carboxylesterase-mediated PA detoxification by specific carboxylesterase 2 inhibitor loperamide (2.5 µM) enhanced lasiocarpine toxicity, whereas the unspecific carboxylesterase inhibitor bis(4-nitrophenyl)phosphate (BNPP, 100 µM)) had a weaker effect. Finally, the inhibition of glutathione-mediated detoxification by buthionine sulphoximine (BSO, 100 µM) strongly enhanced lasiocarpine toxicity in H-4-II-E cells in low and medium, but not in high concentrations. CONCLUSIONS If no toxicity is observed under standard conditions, susceptibility enhancement by using galactose-based media, loperamide, and BSO may be useful to assess relative acute cytotoxicity of PAs in different cell lines.
Collapse
Affiliation(s)
| | | | - Lucia Disch
- Max Zeller Söhne AG, CH-8590 Romanshorn, Switzerland
| | - Beate Siewert
- Max Zeller Söhne AG, CH-8590 Romanshorn, Switzerland
| | | | - Jürgen Drewe
- Max Zeller Söhne AG, CH-8590 Romanshorn, Switzerland; Department of Clinical Pharmacology, University Hospital Basel, CH-4031 Basel, Switzerland.
| |
Collapse
|
16
|
Ogasawara A, Kato N, Torimoto N, Aohara F, Ohashi R, Yamada Y, Taniguchi H. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells. Drug Metab Lett 2018; 12:14-23. [PMID: 29357810 DOI: 10.2174/1872312812666180119114013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 12/28/2017] [Accepted: 01/01/2018] [Indexed: 06/07/2023]
Abstract
BACKGROUND The HepaRG cells have key drug metabolism functionalities comparable to those of primary human hepatocytes. Many studies have reported that this cell line can be used as a reliable in vitro model for human drug metabolism studies, including the assessment of cytochrome P450 (CYP) induction. OBJECTIVES The objective of this study is to determine whether CYP mRNA level measurement is superior to the CYP enzyme activity measurement as a convenient high-throughput method for evaluating CYP induction potential using HepaRG cells. METHODS QuantiGene Plex 2.0 Assay and LC/MS/MS. mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated. RESULTS Although the activities of CYP2B6 and CYP3A were induced by treatment with PB and RIF, we found that the activity of phenacetin O-deethylase (PHOD), which is known as a marker of the activity of CYP1A2, was also enhanced by treatment with these non-CYP1A2 inducers in HepaRG cells. Based on previously published reports, we hypothesized that the expression ratio of CYP3A to CYP1A2 is much higher in HepaRG cells than in human hepatocytes; this may result in a nonnegligible contribution of CYP3A to the PHOD reaction in HepaRG cells. Studies using CYP3A inhibitor and pregnane X receptor-knockout HepaRG cells supported this hypothesis. CONCLUSION The measurement of mRNA serves as a higher reliable indicator for the evaluation of CYP induction potential when using HepaRG cells.
Collapse
Affiliation(s)
- Akira Ogasawara
- Department of Regeneration Medicine, Yokohama City University School of Medicine, Yokohama, Japan
- Research Unit/Innovative Medical Science, Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Toda, Japan
| | - Nozomu Kato
- Translational Research Department, Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Nihonbashi, Japan
| | - Nao Torimoto
- Discovery Technology Laboratories Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Toda, Japan
| | - Fumika Aohara
- Discovery Technology Laboratories Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Toda, Japan
| | - Rikiya Ohashi
- Discovery Technology Laboratories Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Toda, Japan
| | - Yasuhiro Yamada
- Department of Regeneration Medicine, Yokohama City University School of Medicine, Yokohama, Japan
- Department of Clinical Pharmaceutics, Nihon Pharmaceutical University, Kitaadachi, Japan
| | - Hideki Taniguchi
- Department of Regeneration Medicine, Yokohama City University School of Medicine, Yokohama, Japan
| |
Collapse
|
17
|
Hormonal contraceptive + enzyme inducer: unintended pregnancies. Prescrire Int 2017; 26:45. [PMID: 30726632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
|
18
|
Fu G, Zhou C, Wang Y, Fang W, Zhou J, Zhao S, Ma L. Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. Environ Toxicol Pharmacol 2016; 46:188-193. [PMID: 27490210 DOI: 10.1016/j.etap.2016.07.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Revised: 07/18/2016] [Accepted: 07/23/2016] [Indexed: 06/06/2023]
Abstract
In this study with crucian carp (Carassius auratus gibelio), the effect on enrofloxacin (EF) and its metabolite ciprofloxacin (CF) and on the activity of cytochrome P450 1A (CYP1A) and cytochrome P450 3A (CYP3A) was estimated following the oral administration of rifampicin (RIF) (12mg/kg) and β-naphthoflavone (BNF) (12mg/kg), respectively. First, reversed-phase high-performance liquid chromatography (RP-HPLC) was used to detect the pharmacokinetics of EF with continual blood sampling. In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively. In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively. Based on these results for crucian carp, the accumulation and elimination of EF and CF in the RIF-treated group were more rapid than in BNF-treated and control groups. Second, liver microsomes were pretreated with the inducer of CYP1A for BNF and that of CYP3A for RIF, and then the enzymatic activities of CYP1A and CYP3A were measured, respectively. The activities of ethoxyresorufin-O-deethylation (EROD) and erythromycin-N-demethylation (ERND) increased significantly (P<0.05) for CYP1A and CYP3A, respectively. However, in further experiments on the formation of CF, the level of EF N-deethylation was significantly induced by RIF and inhibited by ketoconazole (KTZ) for CYP3A but had no influence for CYP1A, BNF and berberine chloride (BER). We concluded that CYP3A might be responsible for the N-deethylation of EF and because of this activity, could also serve as a toxicity biomarker in crucian carp.
Collapse
Affiliation(s)
- Guihong Fu
- East China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of East China Sea and Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, 300 Jungong Road, Shanghai, 200090, China
| | - Chang Zhou
- East China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of East China Sea and Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, 300 Jungong Road, Shanghai, 200090, China
| | - Yuan Wang
- East China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of East China Sea and Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, 300 Jungong Road, Shanghai, 200090, China
| | - Wenhong Fang
- East China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of East China Sea and Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, 300 Jungong Road, Shanghai, 200090, China.
| | - Junfang Zhou
- East China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of East China Sea and Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, 300 Jungong Road, Shanghai, 200090, China
| | - Shu Zhao
- East China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of East China Sea and Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, 300 Jungong Road, Shanghai, 200090, China
| | - Licai Ma
- East China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of East China Sea and Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, 300 Jungong Road, Shanghai, 200090, China
| |
Collapse
|
19
|
Inhibitors and inducers of CYP enzymes and P-Glycoprotein. Med Lett Drugs Ther 2016; 58:e46-7. [PMID: 27027691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
20
|
Abstract
CONTEXT Kanglaite (KLT) is an oily substance extracted from Coix lacryma-jobi Linn. (Cramineae) and has been proved to significantly improve the life span and quality of life of patients, when combined with chemotherapy, radiotherapy, or surgery. OBJECTIVE The purpose of this study was to find out whether KLT influences the effect on rat cytochrome P450 (CYP) enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4) by using cocktail probe drugs in vivo. MATERIALS AND METHODS A cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), bupropion (20 mg/kg), tolbutamide (5 mg/kg), omeprazole (20 mg/kg), and midazolam (10 mg/kg), was given as oral administration to rats treated with 7 d intraperitoneal injection of KLT. Blood samples were collected at a series of time-points and the concentrations of probe drugs in plasma were determined by HPLC-MS/MS. The corresponding pharmacokinetic parameters were calculated by the software of DAS 2.0 (SPPS Inc., Chicago, IL). RESULTS In the experiment, there was a statistically significant difference in the t1/2, Cmax, AUC(0-∞), and CL for phenacetin, bupropion, tolbutamide, omeprazole, and midazolam. Our study showed that treatment with multiple doses of KLT had induction effect on rat CYP1A2, while CYP2B6, CYP2C9, CYP2C19, and CYP3A4 enzyme activities had been inhibited after multiple doses of KLT treatment. CONCLUSIONS KLT can either induce or inhibit activities of CYP. Therefore, caution is needed when KLT is co-administration with some CYP substrates in clinic, which may result in herb-drug interactions.
Collapse
Affiliation(s)
- Xiaoxiang Du
- The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , China and
| | | | | | | | | |
Collapse
|
21
|
Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm 2015; 72:958-65. [PMID: 25987691 PMCID: PMC4510955 DOI: 10.2146/ajhp140591] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
PURPOSE Potential cytochrome P-450 (CYP) drug-drug interactions in adults with metastatic solid tumors and their effect on eligibility for Phase I clinical trials were characterized. METHODS This study included adult patients with metastatic solid tumors seen by a medical oncologist from January 2008 through July 2011. The medications used by these patients were identified. Each medication's potential for interacting with CYP isozymes was also characterized. Medication changes required to meet Phase I trial eligibility criteria were also reviewed. RESULTS Data from 1773 patients were analyzed: 1489 were not enrolled in a Phase I trial and 284 were enrolled in a Phase I trial. Polypharmacy was significantly more prevalent in the group enrolled in a Phase I trial compared with those not enrolled (95% versus 80%, p < 0.001). The majority of patients not enrolled in a Phase I trial were taking at least one CYP isozyme inhibitor (87%) and at least one CYP isozyme inducer (45%). In a separate analysis, four Phase I trials were evaluated. Of 295 screened patients, 3.2% could not enroll due to concurrent medications. Charts from 74 enrolled patients revealed 655 concurrent medications—93 medications required further review for eligibility involving 51 (69%) of patients. Of the 93 medications, 38 (41%) were stopped and 41 (44%) were changed for the study. CONCLUSION Polypharmacy and the use of medications that interact with CYP isoyzmes were common in adult patients with metastatic solid tumors. Patients enrolling in Phase I studies often require medication changes to meet eligibility requirements.
Collapse
Affiliation(s)
- Kari B Wisinski
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center.
| | - Colby A Cantu
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - Jens Eickhoff
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - Kurt Osterby
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - Amye J Tevaarwerk
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - Jennifer Heideman
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - Glenn Liu
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - George Wilding
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - Susan Johnston
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| | - Jill M Kolesar
- Kari B. Wisinski, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, University of Wisconsin (UW), Madison, and Assistant Professor, UW Carbone Cancer Center, Madison. Colby A. Cantu, B.S., is Medical Student, School of Medicine and Public Health, UW. Jens Eickhoff, Ph.D., is Senior Scientist, Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, UW. Kurt Osterby, B.S., is Senior Decision Support Analyst, UW Hospital and Clinics, Madison. Amye J. Tevaarwerk, M.D., is Assistant Professor of Medicine, School of Medicine and Public Health, UW, and Assistant Professor, UW Carbone Cancer Center. Jennifer Heideman, R.N., is Program Manager, School of Medicine and Public Health, UW, and Program Manager, UW Carbone Cancer Center. Glenn Liu, M.D., is Associate Professor of Medicine, School of Medicine and Public Health, UW, and UW Carbone Cancer Center. George Wilding, M.D., is Professor of Medicine, School of Medicine and Public Health, UW, and Professor, UW Carbone Cancer Center. Susan Johnston, Pharm.D., is Pharmaceutical Research Center Manager, UW Carbone Cancer Center, and UW Hospital and Clinics. Jill M. Kolesar, Pharm.d., is Professor of Pharmacy, School of Pharmacy, UW, and Faculty Supervisor, Analytical Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, UW Carbone Cancer Center
| |
Collapse
|
22
|
Giraudo M, Hilliou F, Fricaux T, Audant P, Feyereisen R, Le Goff G. Cytochrome P450s from the fall armyworm (Spodoptera frugiperda): responses to plant allelochemicals and pesticides. Insect Mol Biol 2015; 24:115-28. [PMID: 25315858 DOI: 10.1111/imb.12140] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Spodoptera frugiperda is a polyphagous lepidopteran pest that encounters a wide range of toxic plant metabolites in its diet. The ability of this insect to adapt to its chemical environment might be explained by the action of major detoxification enzymes such as cytochrome P450s (or CYP). Forty-two sequences coding for P450s were identified and most of the transcripts were found to be expressed in the midgut, Malpighian tubules and fat body of S. frugiperda larvae. Relatively few P450s were expressed in the established cell line Sf9. In order to gain information on how these genes respond to different chemical compounds, larvae and Sf9 cells were exposed to plant secondary metabolites (indole, indole-3-carbinol, quercetin, 2-tridecanone and xanthotoxin), insecticides (deltamethrin, fipronil, methoprene, methoxyfenozide) or model inducers (clofibrate and phenobarbital). Several genes were induced by plant chemicals such as P450s from the 6B, 321A and 9A subfamilies. Only a few genes responded to insecticides, belonging principally to the CYP9A family. There was little overlap between the response in vivo measured in the midgut and the response in vitro in Sf9 cells. In addition, regulatory elements were detected in the promoter region of these genes. In conclusion, several P450s were identified that could potentially be involved in the adaptation of S. frugiperda to its chemical environment.
Collapse
Affiliation(s)
- M Giraudo
- INRA, UMR 1355, Institut Sophia Agrobiotech, Sophia-Antipolis, France; CNRS, UMR 7254, Sophia-Antipolis, France; Université de Nice Sophia Antipolis, Sophia-Antipolis, France; Environment Canada, Centre Saint-Laurent, Montreal, QC, Canada
| | | | | | | | | | | |
Collapse
|
23
|
Murayama N, Usui T, Slawny N, Chesné C, Yamazaki H. Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays. Drug Metab Lett 2015; 9:3-7. [PMID: 25600204 DOI: 10.2174/1872312809666150119104806] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Revised: 12/08/2014] [Accepted: 12/08/2014] [Indexed: 06/04/2023]
Abstract
Recent guidance/guidelines for industry recommend that cytochrome P450 induction can be assessed using human hepatocyte enzyme activity and/or mRNA levels to evaluate potential drug- drug interactions. To evaluate time-dependent cytochrome P450 induction precisely, induction of CYP1A2, CYP2B6, and CYP3A4 mRNA was confirmed (>2-fold) by the treatment with omeprazole, phenobarbital, and rifampicin, respectively, for 24 or 48 h on day 3 from the start of culture. After 24 h, the fold induction of CYP1A2 with 3.6 and 1.8x10(4) HepaRG cells per well was lower than that for 7.2x10(4) cells. CYP1A2 induction levels at 24 h were higher than those after 48 h. In contrast, higher CYP2B6 inductions were confirmed after 48 h exposure than after 24 h, independent of the number of cells per well. To help reduce the use of human cryopreserved hepatocytes, typical P450-dependent enzyme activities were investigated in human HepaRG cells cultured in commercial hanging-drop plates. Newly designed 96-well hanging-drop plates were capable of maintaining human CYP3A-dependent midazolam hydroxylation activities for up to 4 days using only 10% of the recommended initial 7.2x10(4) cells per well. Favorable HepaRG function using hanging-drop plates was confirmed by detecting 1'- hydroxymidazolam O-glucuronide on day 3, suggesting an improvement over traditional control plates in which this metabolite can be detected for 24-well plates. These results suggest that the catalytic function and/or induction of CYP1A2, CYP2B6, and CYP3A4 can be readily assessed with reduced numbers of starting HepaRG cells cultured in three-dimensional cultures in drops prepared with hanging-drop plates.
Collapse
Affiliation(s)
| | | | | | | | - Hiroshi Yamazaki
- Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, 3-3165 Higashi-tamagawa Gakuen, Machida, Tokyo 194-8543, Japan.
| |
Collapse
|
24
|
Zhou XW, Ma Z, Geng T, Wang ZZ, Ding G, Yu-an B, Xiao W. Evaluation of in vitro inhibition and induction of cytochrome P450 activities by hydrolyzed ginkgolides. J Ethnopharmacol 2014; 158 Pt A:132-139. [PMID: 25456428 DOI: 10.1016/j.jep.2014.10.023] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 09/16/2014] [Accepted: 10/13/2014] [Indexed: 06/04/2023]
Abstract
ETHNOPHARMACOLOGICAL RELAVANCE The extracts of Ginkgo biloba leaves are effective in treating cerebral infarction, of which ginkgolides have been demonstrated to be the active ingredients. The purpose of this study was to determine whether hydrolyzed ginkgolides would cause potential drug-drug interactions (DDI) during its clinical use via inhibition or induction of the major human cytochrome P450s (CYPs). MATERIALS AND METHODS The inhibition (direct and metabolism-dependent inhibiton on CYP activities) and induction (mRNA expression level and activity of CYPs) by the hydrolyzed ginkgolides were evaluated in human liver microsomes and cryopreserved human hepatocytes, respectively. RESULTS Within 0.1 to 10μg/mL, the hydrolyzed ginkgolides showed negligible direct inhibition against CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4m (midazolam as substrate) and 3A4t (testosterone as substrate), with IC50 values determined to be >10μg/mL (concentrations expressed as the sum of equivalent concentrations of ginkgolide A, B and K). For the metabolism-dependent inhibition studies, the preincubation of 30min did not substantially alter the IC50 values when compared with the corresponding values in the direct inhibition studies. The activities and mRNA expression levels for CYP1A2 and 2B6 within each drug-treated group (0.1, 1 and 10μg/mL) were not affected after the 48-h incubation. For CYP3A4, the activity and mRNA expression level were not altered when incubated with 0.1 and 1μg/mL of hydrolyzed ginkgolides. When incubated with hydrolyzed ginkgolides at 10μg/mL, the relative activity and relative mRNA expression level of CYP3A4 remarkably increased to 4.59±3.67 and 17.2±9.16-fold of the corresponding vehicle control values, respectively. CONCLUSIONS The hydrolyzed ginkgolides is not likely to cause DDI via inhibition of the major human CYPs. However, the CYP3A4 induction might be clinically relevant.
Collapse
Affiliation(s)
- Xiao-wen Zhou
- The First Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Zheng Ma
- State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Processes, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China
| | - Ting Geng
- State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Processes, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China
| | - Zhen-zhong Wang
- State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Processes, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China
| | - Gang Ding
- State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Processes, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China
| | - Bi Yu-an
- State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Processes, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China
| | - Wei Xiao
- State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Processes, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China.
| |
Collapse
|
25
|
Zhang YW, Bao MH, Hu L, Qu Q, Zhou HH. Dose-response of oridonin on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol 2014; 155:714-720. [PMID: 24933226 DOI: 10.1016/j.jep.2014.06.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2014] [Revised: 05/24/2014] [Accepted: 06/04/2014] [Indexed: 06/03/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Oridonin, the major terpene found in Rabdosia rubescens, is widely used as a dietary supplement or therapeutic drug. The effects of oridonin on drug processing genes, such as cytochrome P450 and nuclear receptors, were still unclear. Therefore, the present study investigated the influence of oridonin on the hepatic drug metabolizing system to evaluate the safety through its drug interaction potential. MATERIALS AND METHODS In this study, eight-week-old male C57BL/6 mice were treated oridonin orally (0, 25, 50, 100, 200 mg/kg, i.g.) for 15 days. The effects of oridonin on major Cyps in mice livers were examined at both the mRNA and enzyme activity levels. RESULTS In general, there are no significant influence of various dose of oridonin on mice liver function. However, oridonin significantly increased Cyps (1a, 2a, 2d, 2e, 2c and 3a family) mRNA expression. In addition, it could induce Cyps activity in microsome incubation at maximum dosage. To our knowledge, it is the first time to identify oridonin as a Cyps inducer in vivo. It also promotes the expression of CAR, PXR and POR. CONCLUSION These results indicate that, if studies in mice extrapolate to humans by orthologous genes, oridonin appears to be a risk to herb-drug interactions due to its induction effects on drug processing genes expression and activation.
Collapse
Affiliation(s)
- Yi-wen Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Xiangya School of Medicine, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, China
| | - Mei-hua Bao
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Xiangya School of Medicine, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, China; Department of Pharmacy, Changsha Medical University, Changsha 410219, China
| | - Lei Hu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Xiangya School of Medicine, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, China
| | - Qiang Qu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Xiangya School of Medicine, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, China
| | - Hong-hao Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Xiangya School of Medicine, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, China.
| |
Collapse
|